Markets:

Overview

News

Currencies

International

Treasuries

AstraZeneca PLC - American Depositary Shares (NQ:AZN)

90.84 +0.98 (+1.09%)

Streaming Delayed Price Updated: 11:33 AM EST, Dec 18, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AstraZeneca PLC - American Depositary Shares

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

74 75 Next >

3 Crazy Good Stocks to Buy With $500 Right Now ↗

June 12, 2024

For investors with only a little money to spare, these three supercharged stocks represent an outrageous opportunity for future growth.

Via InvestorPlace

Healthcare And Biotech Investing: Breakthroughs In The Treatment Of Cancer At ASCO ↗

June 10, 2024

Healthcare stocks underperformed YTD because of weakness in UNH and strength in Technology and Communication Services.

Via Talk Markets

Meet The International Megacaps That 'Match Or Surpass' Magnificent Seven Stocks ↗

June 10, 2024

Five mega companies may offer higher earnings and return potential with lower risk.

Via Investor's Business Daily

TAGRISSO® (osimertinib) granted Priority Review in the US for patients with unresectable, Stage III EGFR-mutated lung cancer

June 10, 2024

From AstraZeneca

Via Business Wire

Week In Review: Structure Reports Efficacy Of Obesity Drug; Raises $476 Million ↗

June 08, 2024

Structure Therapeutics announced positive clinical results for its obesity drug, and then raised $476 million via an offering of its ADSs. Meanwhile, Alphamab Oncology announced a deal with ArriVent...

Via Talk Markets

Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years ↗

June 04, 2024

Via Benzinga

Here's How Much You Would Have Made Owning AstraZeneca Stock In The Last 5 Years ↗

May 22, 2024

Via Benzinga

The No-Brainer Buys: 3 Stocks That Are Absolute Must-Owns Right Now ↗

June 07, 2024

Discover three of the best must-own stocks, showcasing resilient performance, strategic growth initiatives and consistent dividend payouts.

Via InvestorPlace

Exit Strategy: 3 Overvalued Stocks to Sell Before They Deflate ↗

June 06, 2024

These are the overvalued stocks to sell. They represent quality companies that are worth buying after a 20% to 30% downside

Via InvestorPlace

Large Cap BIopharmaceuticals Overview ↗

June 03, 2024

As a defensive play healthcare is weighted at about 12% of the S&P 500.

Via Talk Markets

Topics Stocks

The Gold Rush for Weight Loss Drugs Is Here. These 3 Latecomers Could Be Worth a Buy. ↗

June 03, 2024

There's probably a big enough pie here for everyone to get a slice.

Via The Motley Fool

TAGRISSO® (osimertinib) reduced the risk of disease progression or death by 84% in patients with unresectable, Stage III EGFR-mutated lung cancer vs. placebo in LAURA Phase III trial

June 02, 2024

From AstraZeneca

Via Business Wire

Stocks Seeing Relentless Buying Pressure; Bonds Are Not ↗

June 02, 2024

Relentless buying pressure, to the degree that we saw in Q4 last year, is evidence of strong underlying demand for stocks. Meanwhile, after a 40-year drawdown, the 50-week rate of change for US 30-year...

Via Talk Markets

IMFINZI® (durvalumab) is the first and only immunotherapy to show survival benefit in limited-stage small cell lung cancer in global Phase III trial, reducing the risk of death by 27% vs. placebo

June 02, 2024

From AstraZeneca

Via Business Wire

ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a median progression-free survival of 13.2 months in HR-positive, HER2-low and HER2-ultralow metastatic breast cancer following one or more lines of endocrine therapy

June 02, 2024

From AstraZeneca

Via Business Wire

3 No-Brainer Stocks to Buy in June ↗

June 02, 2024

Now is the time to invest in these great stocks.

Via The Motley Fool

This Pharma Stock Is Poised to Keep Outperforming the S&P 500 ↗

May 30, 2024

AstraZeneca has quietly delivered market-beating results since 2014. Despite skepticism, the company should be able to repeat this feat over the next 10 years.

Via The Motley Fool

Topics Stocks

Amgen Secures FDA Nod For Rare-Disease Treatment Biosimilar Based On AstraZeneca's Drug ↗

May 29, 2024

The FDA has approved Amgen's Bkemv as the first interchangeable biosimilar to AstraZeneca's Soliris for treating rare diseases.

Via Benzinga

AstraZeneca Just Massively One-Upped Pfizer. Here's What It Means for the Stock ↗

May 29, 2024

Both businesses have road maps for the future, but one is better.

Via The Motley Fool

AstraZeneca Plans to Rake in $80 Billion by 2030. Should You Buy the Stock? ↗

May 29, 2024

Its new strategic roadmap aims to catapult the company forward.

Via The Motley Fool

Cellectis Reports Financial Results for First Quarter 2024

May 28, 2024

From Cellectis Inc.

Via GlobeNewswire

Why Is AstraZeneca Stock Trading Lower On Tuesday? ↗

May 28, 2024

AstraZeneca's TROPION-Lung01 phase 3 trial for datopotamab deruxtecan in NSCLC showed OS improvement in nonsquamous patients. While the overall trial did not reach statistical significance.

Via Benzinga

AstraZeneca, Merck, GSK Struck Record $44.1B Licensing Deals With Chinese Drugmakers In 2023: Report ↗

May 27, 2024

Western pharmaceutical companies and investors are driving a record number of licensing deals with Chinese drugmakers.

Via Benzinga

Datopotamab deruxtecan showed clinically meaningful overall survival improvement vs. chemotherapy in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung01 Phase III trial

May 27, 2024

From AstraZeneca

Via Business Wire

Week In Review: Hengrui And Degron Announce $7.2 Billion In Drug Licensings ↗

May 25, 2024

Via Talk Markets

Biden Administration Urges Supreme Court Review in Terrorism Funding Lawsuit Against Pharma Companies ↗

May 23, 2024

U.S. Supreme Court urged by Biden administration to reconsider terrorism funding ruling involving major pharmaceutical and medical equipment companies accused of supporting terrorism in Iraq.

Via Benzinga

Topics Lawsuit

AstraZeneca demonstrates commitment to patients living with amyloidosis at the 2024 International Symposium on Amyloidosis (ISA)

May 23, 2024

From AstraZeneca

Via Business Wire

Tango Therapeutics Shuts Early-Stage Cancer Study Due To Liver Toxicity ↗

May 23, 2024

Tango Therapeutics halts its TNG348 program due to liver toxicity issues found in dose escalation studies. The company will now focus on its PRMT5 program and plans to update on TNG908 and TNG462 later...

Via Benzinga

The RBNZ Maintained Its Hawkish Bias, Leaving The Interest Rate At 5.5% ↗

May 22, 2024

The Reserve Bank of New Zealand kept the official cash rate at 5.5% during its May 2024 policy meeting, extending the rate pause for the 7th straight time and confirming market expectations.

Via Talk Markets

AstraZeneca furthers ambition to transform outcomes in early lung cancer and redefine metastatic breast cancer treatment at ASCO 2024

May 22, 2024

From AstraZeneca

Via Business Wire

< Previous 1 2

...

17 18 19 20 21 22 23 24 25

...

74 75 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.